BACKGROUND: The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting. METHODS: Eligibility included a Zubrod performance status from 0 to 2, no prior gemcitabine or fluoropyrimidine therapy, and normal organ function. Patients received gemcitabine at a dose of 1000 mg/m2 on Days 1, 8, and 15 and capecitabine at a dose of 830 mg/m2 twice daily on Days 1 through 21 on a 28-day cycle with specified dose reductions for baseline renal insufficiency. The primary endpoint was the response rate, which was assessed every 8 weeks. The statistical plan tested the hypothesis that the response rate was 5% versus an alternative of 15%. RESULTS: Sixty patients were enrolled, and 4 of those patients never started treatment. Of the 56 evaluable patients, 79% of patients underwent prior nephrectomy, 75% of patients received prior systemic therapy, and 75% of patients had clear cell histology. Risk stratification revealed that 34%, 43%, and 16% of patients were in Risk Groups 1, 2, and 3, respectively. Toxicity (graded according to the National Cancer Institute's Common Toxicity Criteria [version 2.0]) included Grade 3 or 4 neutropenia in 45% of patients, Grade 2 or greater fatigue in 32% of patients, Grade 2 or greater nausea in 29% of patients, Grade 2 or greater hand-foot reaction in 39% of patients, and Grade 2 or greater diarrhea in 22% of patients. Six patients responded (11%; 95% confidence interval, 4-22%), and the overall median survival was 14.5 months. CONCLUSIONS: Gemcitabine plus capecitabine had modest activity in patients with metastatic renal cancer, although the degree of activity and its associated toxicity would not support further evaluation in a Phase III trial of unselected patients. More focused investigations to identify patients most likely to benefit or to enhance activity with additional agents would be reasonable. (c) 2006 American Cancer Society.
BACKGROUND: The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting. METHODS: Eligibility included a Zubrod performance status from 0 to 2, no prior gemcitabine or fluoropyrimidine therapy, and normal organ function. Patients received gemcitabine at a dose of 1000 mg/m2 on Days 1, 8, and 15 and capecitabine at a dose of 830 mg/m2 twice daily on Days 1 through 21 on a 28-day cycle with specified dose reductions for baseline renal insufficiency. The primary endpoint was the response rate, which was assessed every 8 weeks. The statistical plan tested the hypothesis that the response rate was 5% versus an alternative of 15%. RESULTS: Sixty patients were enrolled, and 4 of those patients never started treatment. Of the 56 evaluable patients, 79% of patients underwent prior nephrectomy, 75% of patients received prior systemic therapy, and 75% of patients had clear cell histology. Risk stratification revealed that 34%, 43%, and 16% of patients were in Risk Groups 1, 2, and 3, respectively. Toxicity (graded according to the National Cancer Institute's Common Toxicity Criteria [version 2.0]) included Grade 3 or 4 neutropenia in 45% of patients, Grade 2 or greater fatigue in 32% of patients, Grade 2 or greater nausea in 29% of patients, Grade 2 or greater hand-foot reaction in 39% of patients, and Grade 2 or greater diarrhea in 22% of patients. Six patients responded (11%; 95% confidence interval, 4-22%), and the overall median survival was 14.5 months. CONCLUSIONS:Gemcitabine plus capecitabine had modest activity in patients with metastatic renal cancer, although the degree of activity and its associated toxicity would not support further evaluation in a Phase III trial of unselected patients. More focused investigations to identify patients most likely to benefit or to enhance activity with additional agents would be reasonable. (c) 2006 American Cancer Society.
Authors: Elizabeth K Chung; Edwin M Posadas; Kristen Kasza; Theodore Karrison; Elizabeth Manchen; Olwen M Hahn; Walter M Stadler Journal: Am J Clin Oncol Date: 2011-04 Impact factor: 2.339
Authors: Stephen L Richey; Pheroze Tamboli; Chaan S Ng; E Lin; Zita D Lim; John C Araujo; Eric Jonasch; Padmanee Sharma; Lance C Pagliaro; Nizar M Tannir Journal: Am J Clin Oncol Date: 2013-10 Impact factor: 2.339
Authors: Abhishek Maiti; Maryam Nemati-Shafaee; Pavlos Msaouel; Lance C Pagliaro; Eric Jonasch; Nizar M Tannir; Amishi Y Shah Journal: Clin Genitourin Cancer Date: 2017-08-10 Impact factor: 2.872
Authors: Eric Jonasch; Lincy S Lal; Bradley J Atkinson; Stacey DaCosta Byfield; Lesley Ann Miller; Lance C Pagliaro; Chun Feng; Nizar M Tannir Journal: BJU Int Date: 2010-09-21 Impact factor: 5.588
Authors: Benelita T Elie; Karen Hubbard; Buddhadev Layek; Won Seok Yang; Swayam Prabha; Joe W Ramos; Maria Contel Journal: ACS Pharmacol Transl Sci Date: 2020-04-09
Authors: Steven Attia; Sherry Morgan-Meadows; Kyle D Holen; Howard H Bailey; Jens C Eickhoff; William R Schelman; Anne M Traynor; Daniel L Mulkerin; Toby C Campbell; Thomas A McFarland; Michael S Huie; James F Cleary; Amye J Tevaarwerk; Dona B Alberti; George Wilding; Glenn Liu Journal: Cancer Chemother Pharmacol Date: 2008-10-08 Impact factor: 3.333